Reliance Gets U.S. Licence To Buy Venezuelan Oil Directly
Q3 Results Impact: Dr Reddy’s Jumps 4%, Eternal 7%, Waaree Energies 10%
Last Updated: 22nd January 2026 - 03:47 pm
Summary:
Dr Reddy’s shares surged over 4% on January 22 after Q3 beat; Eternal jumped 7%, Waaree Energies 10% on strong results amid leadership changes and growth.
Join 5paisa and stay updated with Market News
Dr Reddy’s Laboratories shares surged over 4 % to ₹1,208 on NSE in early trade on Thursday after Q3 results beat estimates. Eternal shares rallied as much as 7.33 % to ₹304.20 on BSE, while Waaree Energies climbed 10 % on robust earnings.
Brokerages turned bullish on Dr Reddy’s domestic strength despite U.S. weakness. Eternal’s profit rose 73 % year-on-year to ₹102 crore, with revenue up 201 % to ₹16,315 crore.
Waaree reported 118.35 % profit growth to ₹1,106.79 crore.
Dr Reddy’s Q3 Beat Drives Gains
Profit fell 14.4% year-on-year to ₹1,209.8 crore, topping Street expectations of ₹1,070 crore. Revenue grew 4.4% to ₹8,726.8 crore, led by a 19% rise in India due to price hikes and the Stugeron brand.
North America dropped 12% due to the Lenalidomide slowdown. EBITDA declined 10.8% to ₹2,049.3 crore, with gross margins at 53.6%.
Eternal Rallies on Profit Surge, CEO Shift
Eternal profit jumped 73% year-on-year to ₹102 crore. Revenue soared 201% to ₹16,315 crore, with 64% like-for-like growth.
Food delivery adjusted revenue rose 26% to ₹2,413 crore; GOV up 21%. EBITDA grew 28% to ₹364 crore.
Shares were flat last month, down 16% in three months, but up 32 % yearly and 453% over three years. Deepinder Goyal resigns as CEO effective February 1.
Waaree Energies Soars on Record Growth
Waaree profit increased 118.35% to ₹1,106.79 crore. Revenue jumped 118.81% to ₹7,565.05 crore; EBITDA rose 167.16% to ₹1,928.15 crore at 25.49% margins.
The firm hit 3.51 GW module and 0.75 GW cell production in Q3.
- Flat ₹20 Brokerage
- Next-gen Trading
- Advanced Charting
- Actionable Ideas
Trending on 5paisa
Indian Market Related Articles
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.
5paisa Capital Ltd